CMX-2043 - Moligand™, ≥96% , CAS No.910627-26-8

CAS: 910627-26-8 Cat. No.: C649672 Fórmula: C₁₆H₂₆N₂O₆S₂ Peso molecular: 406.52 PubChem CID: 49802864

GRADE & PURITY Moligand™, ≥96%

Synonyms

(R)-Lip-L-glu-L-ala-OH | R-lip-ea-oh | R-Lipoic acid-L-glutamate-L-alanine

Storage

Store at -20°C,Argon charged,Desiccated

Shipped In

Ice chest + Ice pads

Visão geral

CMX-2043 is a novel analogue of α-Lipoic Acid . CMX-2043 is effective in antioxidant effect, activation of insulin receptor kinase , soluble tyrosine kinase , and Akt phosphorylation. CMX-2043 shows protection against ischemia-reperfusion injury (IRI) in rat model

In Vitro

CMX-2043 (15-250 mM; 10 min) has great peroxyl radical absorbance capacity. CMX-2043 (1.5 μM) weakly inhibits spleen tyrosine kinase (Syk) and tunica interna endothelial cell kinase (Tie2). CMX-2043 (50 μM; 45 min) activates Akt phosporylation via PI3K pathway in A549 cells. CMX-2043 (2.5 mM; 30 min) diminishes the rise in cytosolic calcium in a concentration-dependent manner in CHO-M1-WT3 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. ImmunofluorescenceCell Line: H9c2 (rat cardiac myocyte) cells Concentration: 50 μM Incubation Time: 3 hours Result: Showed brighter luorescence intensity in cells compared with control, indicating a stronger Akt phosphorylation effect.

In Vivo

CMX-2043 (50-200 mg/kg, 5 mL; p.o.; single dose) reduces myocardial ischemia-reperfusion injury (IRI) as measured by the myocardial infarct to area at risk (MI-AR) ratio and the incidence of arrhythmia. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Ischemia-reperfusion injury (IRI) model in Sprague Dawley ratsDosage: 50, 100, and 200 mg/kg; 5 mL of normal saline solution containing 2% vanilla extract as flavoring Administration: Oral gavage; single dose; induced IRI 30-60 min after treatment Result: Induced arrhythmia and mortality of rats with reducing the ratio of myocardial infarct to area at risk.

Form:Solid

IC50& Target:EC50: 35 μM (IRK), tyrosine kinase, Akt

Specifications

Sinónimos

(R)-Lip-L-glu-L-ala-OH | R-lip-ea-oh | R-Lipoic acid-L-glutamate-L-alanine

Especificações e pureza

Moligand™, ≥96%

Mecanismos bioquímicos e fisiológicos

CMX-2043 is a novel analogue of α-Lipoic Acid ( HY-N0492 ). CMX-2043 is effective in antioxidant effect, activation of insulin receptor kinase , soluble tyrosine kinase , and Akt phosphorylation. CMX-2043 shows protection against ischemia-reperfusion inju

Condições de armazenamento de armazenamento

Store at -20°C,Argon charged,Desiccated

Enviado em

Ice chest + Ice pads

Este produto requer transporte de cadeia fria. Serviços terrestres e outros serviços econômicos não estão disponíveis.

Grau

Moligand™

Tipo de ação

ACTIVATOR

Pureza

≥96%

Nomes e identificadores

• Pubchem Sid: 528763788
• SMILES isoméricas: C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CCCC[C@@H]1CCSS1
• PubChem CID: 49802864
• Peso molecular: 406.52

Mecanismos de ação

Propriedades químicas e físicas

• Solubilidade: DMSO : 20.83 mg/mL (51.24 mM; Need ultrasonic)
• Sensibilidade: Moisture sensitive
• Peso molecular: 406.500 g/mol
• XLogP3: 0.700
• Hydrogen Bond Donor Count: 4
• Hydrogen Bond Acceptor Count: 8
• Rotatable Bond Count: 12
• Exact Mass: 406.123 Da
• Monoisotopic Mass: 406.123 Da
• Topological Polar Surface Area: 183.000 Ų
• Heavy Atom Count: 26
• Formal Charge: 0
• Complexity: 517.000
• Isotope Atom Count: 0
• Defined Atom Stereocenter Count: 3
• Undefined Atom Stereocenter Count: 0
• Defined Bond Stereocenter Count: 0
• Undefined Bond Stereocenter Count: 0
• The total count of all stereochemical bonds: 0
• Covalently-Bonded Unit Count: 1